Alkermes plc — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited consolidated results; amounts below are U.S. dollars. The former oncology business is presented as discontinued operations, and comparative results have been recast.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Total revenue | $350.4 million | $287.6 million |
| Operating income (loss), continuing operations | $43.3 million | $(11.0) million |
| Net income (loss), continuing operations | $38.9 million | $(12.1) million |
| Net income (loss), including discontinued operations | $36.8 million | $(41.8) million |
| Diluted EPS, continuing operations | $0.23 | $(0.07) |
| Diluted EPS, total company | $0.21 | $(0.25) |
| Cash from operating activities | $21.1 million | $(21.3) million |
- Revenue increased 21.8% year over year. Product sales were $233.5 million; manufacturing and royalty revenue was $116.8 million.
- Operating margin from continuing operations was approximately 12.4%, versus approximately negative 3.8% a year earlier. Continuing-operations net margin was approximately 11.1%.
- Cash, cash equivalents and investments totaled $807.9 million at March 31, 2024. Outstanding borrowings were $290.1 million, implying net cash of approximately $517.8 million before other liabilities.
- Current assets were $1.47 billion and current liabilities $459.0 million. Long-term debt was $287.1 million, excluding its $3.0 million current portion. The $291.0 million principal balance of the 2026 Term Loans matures March 12, 2026; the company reported compliance with debt covenants.
- Operating cash flow improved from the prior-year outflow. Investing activities used $40.0 million, primarily for net investment purchases and capital expenditures; financing activities used $17.9 million. Cash declined $36.7 million during the quarter.
Material changes and operating drivers
- Manufacturing and royalty revenue rose $43.9 million, principally reflecting resumed U.S. royalties on long-acting INVEGA products after the 2023 arbitration award. INVEGA royalties were $62.7 million versus $13.6 million; the award also established royalty periods that differ by product.
- Management expects INVEGA SUSTENNA royalties to end August 20, 2024, with a significant impact on those royalties during 2024. Generic-related patent litigation creates further uncertainty for INVEGA SUSTENNA and INVEGA TRINZA.
- Product sales increased $18.8 million. LYBALVI sales rose to $57.0 million from $38.0 million, with reported gross sales growth driven largely by a 50% increase in units and price increases. VIVITROL sales were broadly flat; ARISTADA and ARISTADA INITIO sales declined modestly.
- R&D expense increased $3.8 million to $67.6 million, including higher ALKS 2680 development spending. SG&A increased $11.9 million to $179.7 million, including higher LYBALVI marketing and share-based compensation. The 2024 period also included a $6.8 million modification charge and $2.6 million incremental share-based compensation expense related to performance awards.
- The 2023 comparison included a $29.8 million discontinued-operations loss; Q1 2024 discontinued operations recorded a $2.1 million loss.
Outlook, commentary and risks
- No specific full-year revenue or earnings guidance is provided in the supplied filing text. Management expects existing cash, cash equivalents and investments to fund anticipated working capital and other requirements for at least 12 months after issuance of the financial statements.
- ALKS 2680 is in Phase 2 development for narcolepsy type 1; the company expected to initiate a Phase 2 study in narcolepsy type 2 in the second half of 2024. Development timelines and outcomes remain subject to clinical and regulatory risk.
- The sale of the Athlone, Ireland facility to Novo Nordisk closed May 1, 2024, after quarter-end. The company entered subcontracting arrangements to continue certain activities, potentially through the end of 2025. The facility’s related assets, reported at $96.8 million, were classified as held for sale at quarter-end; the filing text does not provide a clear sale-price value.
- Key legal and regulatory exposures include generic patent litigation involving INVEGA products and VUMERITY, government investigations requesting VIVITROL-related documents, and VIVITROL product-liability cases. The company reported no material litigation losses it considered probable at March 31, 2024, and stated it did not expect existing proceedings to have a material adverse effect; outcomes remain uncertain.
- The company reported the Mural Oncology separation as tax-free based on external tax advice and an IRS private letter ruling. Failure to qualify for tax-free treatment could result in significant liabilities. The company also stated Pillar Two was not expected to have a material impact for the current year.
- A $400 million share repurchase program was authorized in February 2024; no shares were repurchased under it in Q1. The company acquired 960,486 shares at an average $29.52 per share to satisfy employee award tax withholding.
Most important facts for investors to verify
- Confirm the extent to which the Q1 revenue and earnings improvement reflects recurring product demand versus restored INVEGA royalties and other period-specific effects.
- Track the expected August 2024 end of SUSTENNA royalties, the remaining royalty periods for other INVEGA products, and developments in generic patent litigation.
- Assess LYBALVI sales momentum and spending, and monitor the cost and clinical progress of ALKS 2680.
- Review the completed Athlone sale’s proceeds, transition costs and operational impact when disclosed in subsequent filings.
- Monitor operating cash flow, working-capital movements, share repurchases and the 2026 Term Loan maturity and covenants.
- Follow the VIVITROL investigations and product-liability proceedings, VUMERITY patent litigation, and tax risks related to the Mural separation.
Filing detail to note: The statements report total diluted EPS of $0.21; the MD&A executive summary describes continuing-operations EPS of $0.23 as both basic and diluted. The financial statements show diluted continuing-operations EPS of $0.23 and diluted total-company EPS of $0.21.